Copyright
©2010 Baishideng.
World J Gastroenterol. Apr 28, 2010; 16(16): 2046-2054
Published online Apr 28, 2010. doi: 10.3748/wjg.v16.i16.2046
Published online Apr 28, 2010. doi: 10.3748/wjg.v16.i16.2046
Table 1 Clinicopathologic correlation of FAL index around D4S2964
Parameter | FAL index | ||
Low | High | P value | |
Sex | |||
Female | 9 | 9 | 1.000 |
Male | 47 | 47 | |
Serum HBsAg | |||
Negative | 9 | 7 | 0.589 |
Positive | 47 | 49 | |
Cirrhosis | |||
Absent | 10 | 2 | 0.021 |
Present | 42 | 46 | |
Tumor size (cm) | |||
≤ 5 | 12 | 13 | 0.820 |
> 5 | 44 | 43 | |
Tumor stage | |||
I and II | 44 | 41 | 0.608 |
III and IV | 11 | 13 | |
Recurrence | |||
No | 39 | 36 | 0.547 |
Yes | 17 | 20 |
Table 2 Representative clinicopathologic correlation of LOH in different genes around D4S2964
Parameter | LOH | ||
Absent | Present | P value | |
Tumor size (cm) | ART3a | ||
≤ 5 | 16 | 3 | 0.043 |
> 5 | 39 | 27 | |
Tumor size (cm) | NUP54 | ||
≤ 5 | 15 | 6 | 0.019 |
> 5 | 30 | 41 | |
Tumor size (cm) | SCARB2 | ||
≤ 5 | 18 | 3 | 0.001 |
> 5 | 33 | 39 | |
Tumor size (cm) | CCDC158 | ||
≤ 5 | 11 | 3 | 0.037 |
> 5 | 19 | 22 | |
Serum HBeAg | SEPT11 | ||
Negative | 50 | 32 | 0.041 |
Positive | 4 | 9 | |
Serum HBsAg | CCNI | ||
Negative | 11 | 1 | 0.037 |
Positive | 48 | 31 | |
Serum HBeAg | CXCL13 | ||
Negative | 50 | 37 | 0.024 |
Positive | 2 | 8 | |
Recurrence | |||
No | 40 | 26 | 0.044 |
Yes | 12 | 19 | |
Tumor stage | ANXA3 | ||
I and II | 37 | 29 | 0.014 |
III and IV | 15 | 2 | |
Serum HBV-DNA | ARD1B | ||
Negative | 24 | 5 | 0.049 |
Positive | 14 | 10 | |
Recurrence | |||
No | 32 | 9 | 0.046 |
Yes | 7 | 7 | |
Serum HBsAg | SEC31A | ||
Negative | 4 | 10 | 0.013 |
Positive | 47 | 26 | |
Metastasis | |||
No | 40 | 34 | 0.039 |
Yes | 11 | 2 | |
Cirrhosis | HELQ | ||
Absent | 8 | 0 | 0.006 |
Present | 32 | 34 | |
Cirrhosis | AGPAT9 | ||
Absent | 7 | 3 | 0.033 |
Present | 27 | 50 |
Table 3 Univariate analyses of individual parameters for correlations with overall survival rate: Cox proportional hazards model
Parameter | Hazard ratio | 95% CI | P value |
LOH in ARD1B | 2.915 | 1.119-7.594 | 0.029 |
LOH in SEPT11 | 2.856 | 1.354-6.023 | 0.006 |
Sex | 1.327 | 0.518-3.398 | 0.556 |
Tumor grade | 1.693 | 0.948-3.023 | 0.075 |
Serum HBsAg | 0.902 | 0.377-2.158 | 0.817 |
Serum AFP | 3.319 | 1.295-8.504 | 0.012 |
Tumor size | 4.266 | 1.31-13.888 | 0.016 |
No. of nodules | 3.143 | 1.627-6.073 | 0.001 |
Cirrhosis | 0.937 | 0.329-2.673 | 0.903 |
Metastasis | 1.736 | 0.764-3.946 | 0.188 |
Recurrence | 1.992 | 1.049-3.783 | 0.035 |
Table 4 Multivariate analyses of individual parameters for correlations with overall survival rate: Cox proportional hazards model
Parameter | ARD1B | SEPT11 | ARD1B and SEPT11a | ||||||
HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
LOH in ARD1B | 4.615 | 1.538-13.851 | 0.006 | 4.866 | 1.528-15.493 | 0.007 | |||
LOH in SEPT11 | 2.393 | 1.107-5.170 | 0.026 | 0.533 | |||||
Serum AFP | 1.781 | 0.468-6.774 | 0.397 | 2.166 | 0.748-6.274 | 0.154 | 0.208 | ||
Tumor size | 2.146 | 0.459-10.033 | 0.332 | 3.316 | 1.001-10.984 | 0.050 | 0.393 | ||
No. of nodules | 6.173 | 2.072-18.394 | 0.001 | 3.002 | 1.401-6.434 | 0.005 | 5.579 | 1.738-17.904 | 0.004 |
Recurrence | 0.900 | 0.305-2.659 | 0.849 | 1.707 | 0.829-3.516 | 0.147 | 0.859 |
- Citation: Huang GL, Li BK, Zhang MY, Zhang HZ, Wei RR, Yuan YF, Shi M, Chen XQ, Huang L, Li AH, Huang BJ, Li HH, Wang HY. LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. World J Gastroenterol 2010; 16(16): 2046-2054
- URL: https://www.wjgnet.com/1007-9327/full/v16/i16/2046.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i16.2046